177Lu-DOTA-JR11与177Lu-DOTATOC两周期PRRT在原位神经内分泌肿瘤小鼠模型中的多模态成像评估
该研究在表达人SSTR2的原位小鼠胰腺神经内分泌肿瘤模型中,纵向比较了SSTR激动剂177Lu-DOTATOC与拮抗剂177Lu-DOTA-JR11两周期PRRT的疗效。拮抗剂治疗组肿瘤体积显著缩小(P < 0.001),中位生存期延长至207 d(IQR 132-228),而激动剂组为126 d(IQR 118-129)。SPECT/CT显示第一周期拮抗剂肿瘤摄取中位数高4倍、肿瘤/肾脏比值高3倍,第二周期177Lu-DOTATOC肿瘤摄取显著降低(P = 0.01)而拮抗剂保持稳定。
要点
- 177Lu-DOTA-JR11治疗组肿瘤体积显著缩小(P < 0.001),中位生存期207 d优于177Lu-DOTATOC的126 d。
- 第一周期SPECT/CT示拮抗剂肿瘤摄取中位数高4倍、肿瘤/肾脏比值高3倍。
- 第二周期177Lu-DOTATOC肿瘤摄取显著降低(P = 0.01),拮抗剂摄取保持稳定。
核心结论
- 177Lu-DOTA-JR11较177Lu-DOTATOC具有更高的肿瘤/肾脏比值和更明显的细胞毒效应,且两周期治疗中肿瘤摄取更稳定。
研究设计与样本
- 研究在表达人SSTR2的原位小鼠胰腺神经内分泌肿瘤模型中进行,BON-SSTR2细胞用于体内实验。
- 肿瘤小鼠接受2次静脉注射,间隔3周,分别为生理盐水、30 MBq 177Lu-DOTATOC或20 MBq 177Lu-DOTA-JR11。
- 采用每周T2加权MRI监测肿瘤,PRRT后一次18F-FDG PET/MRI评估活力,注射后24 h SPECT/CT测量肿瘤与肾脏摄取。
主要发现
- 与177Lu-DOTATOC相比,177Lu-DOTA-JR11处理导致更多细胞蓄积于G2/M期。
- 拮抗剂组肿瘤体积显著缩小(P < 0.001),中位生存期207 d(IQR 132-228)优于激动剂组126 d(IQR 118-129)。
- 第一周期SPECT/CT显示拮抗剂肿瘤摄取中位数高4倍、肿瘤/肾脏比值高3倍。
- 第二周期177Lu-DOTATOC肿瘤摄取显著降低(P = 0.01),而177Lu-DOTA-JR11摄取保持稳定。
- 18F-FDG PET显示177Lu-DOTA-JR11组存活肿瘤组织最少,为6.2%(IQR 2%-23%)。
临床怎么用
- 在SSTR2表达神经内分泌肿瘤模型中,SSTR拮抗剂177Lu-DOTA-JR11两周期方案显示更高肿瘤/肾脏比值和更稳定摄取,支持其作为PRRT候选方案进一步临床转化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor (SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently, SSTR antagonists have shown promising results for imaging and therapy due to a higher number of binding sites than in commonly used agonists. We evaluated PRRT with SSTR agonist 177Lu-DOTATOC and antagonist 177Lu-DOTA-JR11 longitudinally in an orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2. Morphologic and metabolic changes during treatment were assessed using multimodal imaging, including hybrid PET/MRI and SPECT/CT. Methods: In vitro radioligand binding and internalization assays and cell-cycle analysis were performed. SSTR2-transfected BON cells (BON-SSTR2) were used for in vivo experiments. Tumor-bearing mice received 2 intravenous injections of 100 μL of saline, 30 MBq of 177Lu-DOTATOC, or 20 MBq of 177Lu-DOTA-JR11 with an interval of 3 wk. Weekly T2-weighted MRI was performed for tumor monitoring. Viability of the tumor tissue was assessed by 18F-FDG PET/MRI once after PRRT. Tumor and kidney uptake of the respective radiopharmaceuticals was measured 24 h after injection by SPECT/CT. Results: Compared with 177Lu-DOTATOC, 177Lu-DOTA-JR11 treatment resulted in an increased accumulation of cells in G2/M phase. Animals treated with the SSTR antagonist showed a significant reduction in tumor size (P < 0.001) and an increased median survival (207 d; interquartile range [IQR], 132-228) compared with 177Lu-DOTATOC (126 d; IQR, 118-129). SPECT/CT revealed a 4-fold higher median tumor uptake for the antagonist and a 3-fold higher tumor-to-kidney ratio in the first treatment cycle. During the second therapy cycle, tumor uptake of 177Lu-DOTATOC was significantly lower (P = 0.01) whereas 177Lu-DOTA-JR11 uptake remained stable. Imaging of tumor morphology indicated comparatively larger necrotic fractions for 177Lu-DOTA-JR11 despite further tumor growth. These results were confirmed by 18F-FDG PET, revealing the least amount of viable tumor tissue in 177Lu-DOTA-JR11-treated animals, at 6.2% (IQR, 2%-23%). Conclusion:177Lu-DOTA-JR11 showed a higher tumor-to-kidney ratio and a more pronounced cytotoxic effect than did 177Lu-DOTATOC. Additionally, tumor uptake was more stable over the course of 2 treatment cycles.
引用
- Albrecht J, Exner S, Grötzinger C, et al. Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2020. PMID: 32859703. doi:10.2967/jnumed.120.250274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。